What is the difference between Vyvanse (lisdexamfetamine) and Adderall (amphetamine salts)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Key Differences Between Vyvanse and Adderall

Vyvanse (lisdexamfetamine) is a prodrug that requires enzymatic conversion to active d-amphetamine in the blood, while Adderall (mixed amphetamine salts) contains immediate-release amphetamine that is active upon ingestion. 1

Mechanism and Pharmacology

Chemical Structure

  • Vyvanse is lisdexamfetamine dimesylate—a prodrug consisting of d-amphetamine covalently bonded to the amino acid l-lysine 2, 3
  • Adderall contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine) that are pharmacologically active immediately 1

Activation Process

  • Vyvanse remains pharmacologically inactive until red blood cells enzymatically hydrolyze it to release d-amphetamine and l-lysine 2, 4
  • Adderall requires no conversion and begins working immediately after absorption 5

Pharmacokinetic Profile

  • Vyvanse has a delayed onset with a lag time approximately 0.6 hours longer and reaches peak levels about 1.1 hours later than equivalent doses of d-amphetamine 5
  • Adderall (immediate-release formulations) reaches peak concentrations more rapidly 5
  • Both achieve similar maximal concentrations and total drug exposure (AUC) when given in equimolar doses 5

Clinical Implications

Duration of Action

  • Vyvanse provides once-daily dosing with effects lasting up to 14 hours post-dose in adults, making it suitable for managing symptoms extending late into the day 4
  • Adderall XR (extended-release) also provides once-daily dosing but through different controlled-release bead technology 1

Abuse Potential

  • Vyvanse has theoretically lower oral abuse potential because the prodrug design limits the rate of d-amphetamine release through enzymatic hydrolysis 1, 3
  • The American Academy of Pediatrics notes that lisdexamfetamine is more difficult to extract for misuse compared to immediate-release amphetamines 1
  • However, research shows that when taken orally at therapeutic doses, peak subjective effects (drug liking, euphoria) are similar between lisdexamfetamine and d-amphetamine, just delayed in onset 5
  • Adderall immediate-release formulations have higher diversion risk, particularly in adolescents 1

Dosing Considerations

Vyvanse: 1

  • Starting dose: 20-30 mg once daily in the morning
  • Titration: Increase by 10 mg weekly
  • Maximum: 70 mg daily

Adderall XR: 1

  • Starting dose: 10 mg once daily in the morning
  • Titration: Increase by 5 mg weekly
  • Maximum: 50 mg daily

Side Effect Profile

  • Both medications produce similar adverse effects including decreased appetite, sleep disturbances, increased blood pressure and heart rate, headaches, irritability, and stomach pain 1
  • Both require monitoring of blood pressure, heart rate, weight, and height in children 1, 6
  • Peak cardiovascular and subjective stimulant effects occur later with Vyvanse but reach similar magnitudes as Adderall 5

Special Populations

Pregnancy and Lactation

  • Both medications have similar safety profiles in pregnancy with reassuring data regarding major congenital malformations 1
  • Both carry possible small increased risks for gastroschisis, preeclampsia, and preterm birth when used in the second half of pregnancy 1
  • Both are classified as Hale lactation risk category L3 1
  • Limited published data exists specifically for lisdexamfetamine in pregnancy, but since it converts to dextroamphetamine, the amphetamine safety data applies 1

Adolescents at Risk for Diversion

  • Vyvanse is preferred when diversion risk is a concern because the prodrug formulation makes extraction more difficult and provides no advantage when crushed or snorted 1
  • Adderall immediate-release has higher diversion potential 1

Common Pitfalls

  • Do not assume Vyvanse has dramatically lower abuse potential—while the prodrug design delays onset, oral administration produces similar peak subjective effects as d-amphetamine 5
  • Both medications require the same cardiovascular monitoring—neither is safer regarding blood pressure or heart rate effects 1, 6, 5
  • Do not use interchangeable dosing—Vyvanse doses are not equivalent to Adderall doses due to different salt formulations and the prodrug design 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Lisdexamfetamine.

Paediatric drugs, 2007

Guideline

Cardiovascular and Central Nervous System Effects of Adderall XR

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.